Topotecan, un nuovo farmaco per il trattamento del carcinoma epiteliale dell'ovaio

Translated title of the contribution: Topotecan, a new drug for the treatment of epithelial ovarian carcinoma

Giovanna Scarfone, Antonella Villa, Serenella Morana

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Topotecan, a semi-synthetic derivative of camptothecin, is an antitumor drug with topoisomerase I-inhibitory preclinical activity against various tumor types. The antitumor effect of topotecan in preclinical models was shown to be administration schedule-dependent as repeated bolus injections proved more effective than a single infusion. A number of different dosing schedules are being investigated in clinical trials including oral administration, a daily infusion on 5 consecutive days and a continuous infusion for 21 days. Previous studies of topotecan showed activity against platinum-resistant ovarian cancer using this variety of schedules. The five- daily schedule repeated every 21 days was identified for further Phase II trials because it seemed to show the greatest activity in Phase I trials, with myelosuppression, mostly neutropenia, as dose-limiting toxicity. Phase II studies confirmed the antitumor activity of topotecan in platinum-failed diseases with an overall response rate ranging from 14% to 25%. A randomized Phase III study comparing topotecan with paclitaxel showed topotecan to have a higher response rate, 20.5% versus 13.2% (P=.138). Median times to progression were 23 and 14 weeks, respectively, for topotecan and paclitaxel (P=.002). Median survival was 61 weeks for topotecan and 43 weeks for paclitaxel (P=.515). Neutropenia was significantly more frequent in the topotecan arm than in the paclitaxel arm (79% vs 23%). Conclusion: topotecan in a daily administration for five days is an effective regimen as second- line treatment in ovarian carcinoma. Its efficacy manifested by higher response rates and significantly longer time to progression is comparable to paclitaxel. Further investigations on topotecan in ovarian cancer, including first-line use and combination with other active agents, are needed.

Original languageItalian
JournalTumori
Volume83
Issue number6 SUPPL. 2
Publication statusPublished - Nov 1997

Fingerprint

Topotecan
Carcinoma
Pharmaceutical Preparations
Paclitaxel
Appointments and Schedules
Therapeutics
Neutropenia
Platinum
Ovarian Neoplasms
Camptothecin
Type I DNA Topoisomerase
Antineoplastic Agents
Oral Administration

ASJC Scopus subject areas

  • Cancer Research

Cite this

Topotecan, un nuovo farmaco per il trattamento del carcinoma epiteliale dell'ovaio. / Scarfone, Giovanna; Villa, Antonella; Morana, Serenella.

In: Tumori, Vol. 83, No. 6 SUPPL. 2, 11.1997.

Research output: Contribution to journalArticle

Scarfone, Giovanna ; Villa, Antonella ; Morana, Serenella. / Topotecan, un nuovo farmaco per il trattamento del carcinoma epiteliale dell'ovaio. In: Tumori. 1997 ; Vol. 83, No. 6 SUPPL. 2.
@article{b8d62bb8aa904c2898a706c92e96982d,
title = "Topotecan, un nuovo farmaco per il trattamento del carcinoma epiteliale dell'ovaio",
abstract = "Topotecan, a semi-synthetic derivative of camptothecin, is an antitumor drug with topoisomerase I-inhibitory preclinical activity against various tumor types. The antitumor effect of topotecan in preclinical models was shown to be administration schedule-dependent as repeated bolus injections proved more effective than a single infusion. A number of different dosing schedules are being investigated in clinical trials including oral administration, a daily infusion on 5 consecutive days and a continuous infusion for 21 days. Previous studies of topotecan showed activity against platinum-resistant ovarian cancer using this variety of schedules. The five- daily schedule repeated every 21 days was identified for further Phase II trials because it seemed to show the greatest activity in Phase I trials, with myelosuppression, mostly neutropenia, as dose-limiting toxicity. Phase II studies confirmed the antitumor activity of topotecan in platinum-failed diseases with an overall response rate ranging from 14{\%} to 25{\%}. A randomized Phase III study comparing topotecan with paclitaxel showed topotecan to have a higher response rate, 20.5{\%} versus 13.2{\%} (P=.138). Median times to progression were 23 and 14 weeks, respectively, for topotecan and paclitaxel (P=.002). Median survival was 61 weeks for topotecan and 43 weeks for paclitaxel (P=.515). Neutropenia was significantly more frequent in the topotecan arm than in the paclitaxel arm (79{\%} vs 23{\%}). Conclusion: topotecan in a daily administration for five days is an effective regimen as second- line treatment in ovarian carcinoma. Its efficacy manifested by higher response rates and significantly longer time to progression is comparable to paclitaxel. Further investigations on topotecan in ovarian cancer, including first-line use and combination with other active agents, are needed.",
keywords = "Refractory, Resistant and relapsed ovarian cancer, Topotecan",
author = "Giovanna Scarfone and Antonella Villa and Serenella Morana",
year = "1997",
month = "11",
language = "Italian",
volume = "83",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6 SUPPL. 2",

}

TY - JOUR

T1 - Topotecan, un nuovo farmaco per il trattamento del carcinoma epiteliale dell'ovaio

AU - Scarfone, Giovanna

AU - Villa, Antonella

AU - Morana, Serenella

PY - 1997/11

Y1 - 1997/11

N2 - Topotecan, a semi-synthetic derivative of camptothecin, is an antitumor drug with topoisomerase I-inhibitory preclinical activity against various tumor types. The antitumor effect of topotecan in preclinical models was shown to be administration schedule-dependent as repeated bolus injections proved more effective than a single infusion. A number of different dosing schedules are being investigated in clinical trials including oral administration, a daily infusion on 5 consecutive days and a continuous infusion for 21 days. Previous studies of topotecan showed activity against platinum-resistant ovarian cancer using this variety of schedules. The five- daily schedule repeated every 21 days was identified for further Phase II trials because it seemed to show the greatest activity in Phase I trials, with myelosuppression, mostly neutropenia, as dose-limiting toxicity. Phase II studies confirmed the antitumor activity of topotecan in platinum-failed diseases with an overall response rate ranging from 14% to 25%. A randomized Phase III study comparing topotecan with paclitaxel showed topotecan to have a higher response rate, 20.5% versus 13.2% (P=.138). Median times to progression were 23 and 14 weeks, respectively, for topotecan and paclitaxel (P=.002). Median survival was 61 weeks for topotecan and 43 weeks for paclitaxel (P=.515). Neutropenia was significantly more frequent in the topotecan arm than in the paclitaxel arm (79% vs 23%). Conclusion: topotecan in a daily administration for five days is an effective regimen as second- line treatment in ovarian carcinoma. Its efficacy manifested by higher response rates and significantly longer time to progression is comparable to paclitaxel. Further investigations on topotecan in ovarian cancer, including first-line use and combination with other active agents, are needed.

AB - Topotecan, a semi-synthetic derivative of camptothecin, is an antitumor drug with topoisomerase I-inhibitory preclinical activity against various tumor types. The antitumor effect of topotecan in preclinical models was shown to be administration schedule-dependent as repeated bolus injections proved more effective than a single infusion. A number of different dosing schedules are being investigated in clinical trials including oral administration, a daily infusion on 5 consecutive days and a continuous infusion for 21 days. Previous studies of topotecan showed activity against platinum-resistant ovarian cancer using this variety of schedules. The five- daily schedule repeated every 21 days was identified for further Phase II trials because it seemed to show the greatest activity in Phase I trials, with myelosuppression, mostly neutropenia, as dose-limiting toxicity. Phase II studies confirmed the antitumor activity of topotecan in platinum-failed diseases with an overall response rate ranging from 14% to 25%. A randomized Phase III study comparing topotecan with paclitaxel showed topotecan to have a higher response rate, 20.5% versus 13.2% (P=.138). Median times to progression were 23 and 14 weeks, respectively, for topotecan and paclitaxel (P=.002). Median survival was 61 weeks for topotecan and 43 weeks for paclitaxel (P=.515). Neutropenia was significantly more frequent in the topotecan arm than in the paclitaxel arm (79% vs 23%). Conclusion: topotecan in a daily administration for five days is an effective regimen as second- line treatment in ovarian carcinoma. Its efficacy manifested by higher response rates and significantly longer time to progression is comparable to paclitaxel. Further investigations on topotecan in ovarian cancer, including first-line use and combination with other active agents, are needed.

KW - Refractory

KW - Resistant and relapsed ovarian cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0031422973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031422973&partnerID=8YFLogxK

M3 - Articolo

VL - 83

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6 SUPPL. 2

ER -